It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...
This article was reviewed by Knox Beasley, MD. Flakes on your scalp making you feel self-conscious? Let’s talk about seborrheic dermatitis vs dandruff. Whether your scalp feels like a snowglobe thanks ...
Please provide your email address to receive an email when new articles are posted on . Malassezia yeast may not be the root cause of seborrheic dermatitis. A new study showed that Zoryve was a ...
NEW YORK — Topical antifungals should no longer be considered a first-line therapy for seborrheic dermatitis for two reasons: Topical anti-inflammatories have replaced them, and rates of ...
Our stories are reviewed by medical professionals to ensure you get the most accurate and useful information about your health and wellness. For more information, visit our medical review board. This ...
Medically reviewed by Marisa Garshick, MD Wet dandruff symptoms may worsen with hormonal changes, stress, or cold, dry weather. Diagnosis involves checking the scalp for flaking, oiliness, and redness ...
Arcutis Biotherapeutics launched a campaign Monday focused on seborrheic dermatitis, highlighting personal journeys from patients with the disease as well as tips from dermatologists. The Clearing Up ...
NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foam If approved, roflumilast foam would be the first topical drug for seborrheic ...
Seborrheic dermatitis may disrupt the skin barrier, potentially exposing patients to other epithelial barrier diseases (EBDs) across various organ systems. A large cohort study found positive ...
About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.
The U.S. Food and Drug Administration (FDA) has approved the topical foam Zoryve (roflumilast) to treat an inflammatory skin condition known as seborrheic dermatitis, commonly called scalp eczema, ...
Seborrheic dermatitis is positively associated with a range of epithelial barrier diseases, including dermatologic, respiratory, gastrointestinal, and ocular diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback